VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers

Nilofer Azad, MD
Published Online: 7:21 PM, Sat November 11, 2017

Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.